HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BioNTech (NASDAQ:BNTX) and maintained a price target of $113.
June 04, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BioNTech and maintained a price target of $113, indicating continued confidence in the company's stock performance.
The reiteration of a Buy rating and maintenance of a $113 price target by HC Wainwright & Co. suggests that the analyst firm has a positive outlook on BioNTech's future performance. This could lead to increased investor confidence and potentially a short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100